Skip to main content
Spyre Therapeutics, Inc. logo

Spyre Therapeutics, Inc. — Investor Relations & Filings

Ticker · SYRE ISIN · US00773J1034 LEI · 52990017AIJPRH3HQH40 US Manufacturing
Open in API
Filings indexed 740 across all filing types
Latest filing 2024-03-14 Capital/Financing Update
Country US United States of America
Listing US SYRE

About Spyre Therapeutics, Inc.

https://spyre.com/

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapeutics for patients with inflammatory bowel disease (IBD) and other immune-mediated conditions. The company's approach involves engineering novel antibodies with prolonged activity in the body, which allows for less frequent dosing. Its pipeline targets validated biological mechanisms and explores the use of these antibodies as both monotherapies and in rational combination therapies. Spyre aims to provide treatment options for various gastrointestinal and rheumatic diseases that offer the potential for enhanced efficacy and greater convenience.

Recent filings

Filing Released Lang Actions
S-1/A
Capital/Financing Update Classification · 95% confidence The document is a Pre-Effective Amendment No. 3 to a Form S-1 Registration Statement filed with the SEC by Spyre Therapeutics, Inc. It is a registration statement under the Securities Act of 1933, related to the offering of common stock by selling stockholders. The document includes a preliminary prospectus with detailed information about the offering, risk factors, management discussion and analysis, business description, executive compensation, and other disclosures typical of a registration statement for securities offerings. This type of filing is a capital markets document related to fundraising and securities registration, not a financial report, earnings release, or management report. Therefore, it fits best under the category Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2024-03-14 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-03-11 English
Regulatory Filings 2024
Regulatory Filings Classification · 50% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. There is no indication of the document being a report itself or an announcement. Given the lack of identifiable information and the fallback rule for documents that do not fit any specific category, the appropriate classification is Regulatory Filings (RNS). The confidence is moderate due to the inability to analyze the content meaningfully.
2024-03-09 English
POS AM
Regulatory Filings Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to a Form S-1 Registration Statement filed with the SEC by Spyre Therapeutics, Inc. It updates the registration statement to include the FY23 financial statements based on the company's Form 10-K for the year ended December 31, 2023, and updates other disclosures. The document is a regulatory filing related to securities registration and offering, specifically a registration statement amendment under the Securities Act of 1933. It is not an annual report (10-K) itself, nor an earnings release or other financial report. It is a formal SEC filing related to capital markets and securities registration. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it contains detailed legal and regulatory information typical of an SEC registration statement amendment.
2024-03-05 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a letter from Gibson, Dunn & Crutcher LLP responding to comments from the U.S. Securities and Exchange Commission (SEC) Division of Corporation Finance regarding an Amendment No. 1 to a Registration Statement on Form S-1 filed by Spyre Therapeutics, Inc. The letter addresses SEC staff comments on various disclosures in the Registration Statement and the related Amendment No. 2. The document references regulatory review and revisions to the Registration Statement, which is a filing related to securities registration, not a financial report or earnings release. It is correspondence responding to SEC comments on a registration filing, which fits the category of Regulatory Filings (RNS). The document is not an Annual Report, Earnings Release, or any other specific report type but rather a regulatory correspondence letter. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2024-03-01 English
S-1/A
Regulatory Filings Classification · 95% confidence The document is a "Pre-Effective Amendment No. 2 to Form S-1 Registration Statement" filed with the SEC, which is a registration statement under the Securities Act of 1933. It is a preliminary prospectus related to the resale of shares by selling stockholders, describing the offering, risk factors, management discussion, and other disclosures typical of a registration statement for securities offerings. It is not a financial report, earnings release, or management discussion report. It is a regulatory filing related to securities registration and offering. The document length is 15,000 characters, and it is a full filing, not a short announcement. The document does not contain financial statements or detailed financial analysis but is primarily a registration statement and prospectus. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories, including registration statements and prospectuses.
2024-03-01 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.